← Leaderboards
Patricia Devaux
Mayo Clinic Rochester
$2,961,490
Attributed
$2,961,490
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $318K · FY2008–25$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,961,490 · 6
By mechanism
R21$1,689,490 · 4
R01$954,000 · 1
R56$318,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Carmen M Terzic$1,881,195
- Evanthia Galanis$13,573,895
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsGenesProductionMeasles VirusViralVectorGenomeGenerationsFibroblastsRegenerative MedicineModificationViral VectorBaseInduced Pluripotent Stem CellLeadRna VirusesInnovationHematopoietic Stem CellsMeaslesFutureSomatic CellCrispr/Cas TechnologyGuide RnaHematological Disease
Grant awards (12)
Next generation of delivery platform for Prime editors based on an RNA vector for Sickle cell disease: the âall-in-oneâ vector$181,575
R21 · FY2025 · EB · contact PI
Next generation of delivery platform for Prime editors based on an RNA vector for Sickle cell disease: the âall-in-oneâ vector$217,890
R21 · FY2024 · EB · contact PI
Single non-integrating RNA vector for gene editing and reprogramming of Fanconi anemia fibroblasts$318,000
R01 · FY2022 · HL · contact PI
Single non-integrating RNA vector for gene editing and reprogramming of Fanconi anemia fibroblasts$318,000
R01 · FY2021 · HL · contact PI
Single non-integrating RNA vector for gene editing and reprogramming of Fanconi anemia fibroblasts$318,000
R01 · FY2020 · HL · contact PI
Single non-integrating RNA vector for gene editing and reprogramming of Fanconi anemia fibroblasts$318,000
R56 · FY2019 · HL · contact PI
Measles virus as a tool for iPSC-independent tissue specific reprogramming$238,500
R21 · FY2016 · AI · contact PI
Measles virus as a tool for iPSC-independent tissue specific reprogramming$198,750
R21 · FY2015 · AI · contact PI
Measles vectors for genomic modification-free induced pluripotent stem cells$238,500
R21 · FY2014 · AI · contact PI
Measles vectors for genomic modification-free induced pluripotent stem cells$198,750
R21 · FY2013 · AI · contact PI
Control of innate immunity and apoptosis by Measles virus P, V and C proteins$264,425
R21 · FY2009 · AI · contact PI
Control of innate immunity and apoptosis by Measles virus P, V and C proteins$151,100
R21 · FY2008 · AI · contact PI